BPMX BioPharmX Corporation. Common

+0  (6%)
Previous Close 0.69
Open 0.71
Price To book 13.27
Market Cap 41.45M
Shares 56,782,000
Volume 1,281,203
Short Ratio 2.83
Av. Daily Volume 1,225,120

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated in 2017
Moderate to severe periodic breast pain associated with FBC (fibrocystic breast condition) and cyclic mastalgia
Noted April 20, 2017 that data are due "early May 2017" - last estimated possible date May 15 based on company guidance of "early May".

Latest News

  1. BioPharmX Completes Last Subject Visit in its Phase 2b Trial of BPX-01, Expects to Report Topline Results First Half of May 2017
  2. BioPharmX AACR Poster Will Present Findings Suggesting Molecular Iodine Inhibits Breast Cancer Cell Growth and Drives Cancer Cell Death
  3. BioPharmX Reports Fourth Quarter and Full Year 2017 Financial Results
  4. BioPharmX Invited to Present at 27th Annual Oppenheimer Healthcare Conference
  5. BioPharmX to Report Fourth Quarter and Full Year Financial Results
  6. BioPharmX Society of Toxicology Poster Suggests Promise of BPX-01 as Topical Acne Therapy, Highlights Safety
  7. BioPharmX to Present at 29th Annual ROTH Conference
  8. BioPharmX Presents Poster at American Academy of Dermatology Annual Meeting Suggesting BPX-01 Safely, Efficiently Delivers Acne-Fighting Minocycline to Pilosebaceous Units
  9. SPIE Photonics West Presentations to Show BioPharmX was First to Visualize Minocycline on the Skin Using Multiphoton Microscopy
  10. Specialty Pharma Industry Veteran Charles Gregory Vontz Joins BioPharmX Board of Directors
  11. BioPharmX Data Suggest Anti-Inflammatory Activity of BPX-01 Topical Minocycline Gel
  12. BioPharmX Completes Enrollment of BPX-01 Phase 2b OPAL Clinical Trial for Acne Vulgaris
  13. BioPharmX (BPMX) Exited Fiscal Third Quarter with Strong Balance Sheet
  14. BioPharmX Corporation Reports Third Quarter Financial Results
  15. ETFs with exposure to BioPharmX Corp. : December 13, 2016
  16. These 5 Stocks Under $10 Could Make You a Lot of Money
  17. BioPharmX to Report Third Quarter Financial Results
  18. BioPharmX Presents Research at Cell Biology 2016 Showing How Molecular Iodine Promotes Breast Health by Attacking Fibrocystic Breast Tissue
  19. BioPharmX Corporation Announces Closing of a $12.5 Million Unit Offering
  20. BioPharmX Presents BPX-01 Topical Minocycline Gel Acne Data at SDEF's 17th Annual Las Vegas Dermatology Seminar